Dr. Neville's fellowship is again a clear indication that microbiologists are making the effort to get PBT2 to the market, not the neurodegeneration specialists of ATH. I am sure there will be more to come, urinary infections would be a good target, IMO. In spite of Dr. Neville being from Melbourne, she is a part of the Queensland microbiology group, and sure she will be supported also by that team and perhaps also by Uniquest.
Dr. Neville's fellowship is again a clear indication that...
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $1.528K | 317.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 102 | 97511267 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 31179254 | 15 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |